Published studies indicate the MTHFR C677T and A1298C polymorphisms are associated with abnormal homocysteine levels, which may cause various pregnancy complications and birth defects. However, the results obtained from different studies have been inconsistent. Therefore, this meta-analysis explores the association between MTHFR polymorphisms and birth defects and adverse pregnancy outcomes. The PubMed, ScienceDirect, Embase, and China Biology Medicine literature databases and ClinicalTrials were searched. Analyses of public bias, meta-regression, subgroups, and sensitivity were used to ensure the robustness of our results. MTHFR C677T was significantly associated with recurrent pregnancy loss in developing countries (odds ratio [OR], 1.34; 95% confidence interval [CI], 1.20-1.50) but not in developed countries (OR, 0.87; 95% CI, 0.68-1.11). No significant relationship was found between MTHFR A1298C and recurrent pregnancy loss (OR, 1.04; 95% CI, 0.93-1.18). MTHFR C677T and A1298C were not associated with preeclampsia (OR, 1.06; 95% CI, 0.97-1.16 and OR, 1.16; 95% CI, 0.97-1.39, respectively), and C677T was not associated with placental abruption (OR, 1.03; 95% CI, 0.87-1.21), intrauterine growth retardation (OR, 1.02; 95% CI, 0.90-1.15), or congenital heart disease (OR, 1.05; 95% CI, 0.89-1.25). MTHFR C677T, but not A1298C, was associated with neural tube defects (OR, 1.24; 95% CI, 1.08-1.42) and Down syndrome (OR, 1.65; 95% CI, 1.39-1.95).
| INTRODUCTION
Folic acid (folate) is one of the B vitamins required by biological systems to synthesize DNA and RNA and metabolize amino acids. Folic acid can only be obtained from diet, and a higher dose is required during pregnancy as cells grow and proliferate rapidly. The daily recommended amount of folic acid for all women of childbearing age by health authorities in most countries is 0.4 mg (400 μg). 1 The folate derivatives formed during folate metabolism are substrates in single-carbon-transfer reactions and also involved in the synthesis of DNA. 2 Folic acid is reduced to dihydrofolate, which is then reduced to tetrahydrofolate (FH4). FH4 forms 5,10-methylene-THF through the addition of a methylene bridge from formate, serine, or glycine. Subsequently, 5,10-methylene-THF is irreversibly reduced to 5-methyl-THF by methylenetetrahydrofolate reductase (MTHFR).
In addition, 5,10-methylene-THF is used to convert homocysteine (Hcy) into methionine by methionine synthase, which maintains Yuan Zhang, Xia He, and Xuan Xiong contributed equally to this manuscript and should be considered as co-first authors. blood Hcy at a normal level, 3 as shown in Figure 1 . A high level of Hcy in the blood, known as hyperhomocysteinemia, is suggested to be related to pregnancy complications and adverse outcomes, as well as cardiovascular disease, neuropsychiatric illness, and cancer. [4] [5] [6] [7] [8] [9] [10] [11] [12] It has been suggested that a cause of hyperhomocysteinemia is genetic polymorphism in MTHFR, and 10% to 20% of the population is homozygous for MTHFR 677C>T or 1298A>C. 13 The MTHFR gene is located on chromosome 1p36.3 and contains 11 exons. To date, hundreds of DNA sequence variants have been reported for this gene, where the two most-investigated single nucleotide polymorphisms are C677T (rs1801133) and A1298C (rs1801131). The 677T
allele causes a valine substitution of alanine at amino acid 222, resulting in an enzyme with reduced activity. The TT homozygote and CT heterozygote of MTHFR have only 10% to 20% and 65% efficiency, respectively, processing folic acid as compared with the wild type (the CC genotype). 14 The 1298C allele leads to an alanine substitution of glutamate at amino acid 429. However, whether the activity and thermolability of the enzyme are changed remains controversial. 14, 15 In this study, we assessed the risk of mothers carrying the MTHFR C677T and A1298C mutations having a child born with birth defects and adverse pregnancy outcomes (APOs). The birth defects analyzed in this study were neural tube defects (NTDs), congenital heart disease (CHD), and Down syndrome (DS), and the APOs chosen were recurrent pregnancy loss (RPL), preeclampsia (PE), placental abruption (PA), and intrauterine growth retardation (IUGR).
In terms of female reproductive pathophysiology, a mother carrying the mutant alleles of MTHFR may have associated birth defects and APOs, including RPL, PE, and preterm delivery, and even neurodevelopmental disorders, in their offspring. 16, 17 However, this correlation remains unclear, and this meta-analysis aims to fully investigate the association between the two most-investigated variants of MTHFR and several common APOs and birth defects. Chinese up until March 2018. The search terms were "Pregnancy"
AND "MTHFR" AND "polymorphism" OR "variants." For unpublished studies, we have searched "ClinicalTrials.gov" database by using FIGURE 1 Simplified folate metabolism pathway and relationship to birth defects and adverse pregnant outcomes. Folate (folic acid) is reduced to dihydrofolate (DHF), which is then reduced to tetrahydrofolate (FH4). FH4 then formed 5,10-methylene-THF by the addition of a methylene bridge from formate, serine, or glycine. 5,10-Methylene-THF is irreversibly reduced to 5-methyl-THF by the methylenetetrahydrofolate reductase (MTHFR). 5,10-Methylene-THF is used to convert homocysteine (Hcy) to methionine by the methionine synthase, keeping blood homocysteine at a normal level. FTHF, 10-formyltetrahydrofolate; MTR, methionine synthase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine
What's already known about this topic?
• The MTHFR C677T and A1298C polymorphisms, leading to protein dysfunction, are associated with abnormal homocysteine levels. However, the relationship with adverse pregnancy outcomes and birth defects is unclear.
What does this study add?
• From the present study, we have found that (1) MTHFR C677T mutation is associated with RPL in developing but not developed countries and with NTD and DS and (2) the impact of such associations is moderate.
search term "MTHFR" in "Other Terms" and screened the content under "Study Title," "Conditions," and "Interventions" for eligible stud- C677T and nine A1298C studies for NTDs, 10 C677T and two A1298C studies for CHD, 11 C677T and nine A1298C studies for DS, 33 C677T and 13 A1298C studies for RPL, 34 C677T and eight A1298C studies for PE, eight C677T and three A1298C studies for PA, and seven C677T and three A1298C studies for IUGR ( Figure 2 ).
The associations between A1298C and CHD, and PA and IUGR were not explored because of the paucity of studies (less than four) on the subject. The Newcastle-Ottawa Scale was used to assess the quality of the studies. Only studies rating ≥5 stars were included. Disagreement at any stage of data searching was resolved by discussion between the two reviewers.
| Data extraction
Two reviewers independently carried out the data extraction. The following information from each eligible publication was recorded: name of the first author, year of publication, country, frequency of genotypes in both case and control groups, genotyping methods, and categories of birth defects or APOs.
| Data analysis
OR and 95% CI were used to determine the strength of the association between the two gene polymorphisms in MTHFR and APOs.
According to the methods described by Thakkinstian et al, calculating
and comparing the ORs of TT vs CC (OR 1 ), CT vs CC (OR 2 ), and TT vs CT (OR 3 ) for C677T and CC vs AA (OR 1 ), AC vs AA (OR 2 ), and CC vs AC (OR 3 ) for A1298C were carried out to determine the best genetic model. 22 Heterogeneity between studies was calculated using the chisquare-based "Q" test and inconsistency value (I 2 ). A P < 0.05 for the Q statistic or I 2 ≥ 50% was considered significant for heterogeneity.
Data from eligible studies were combined using inverse variance by a random-effects model if I 2 ≥ 50%; otherwise, a fix-effects model was used. A meta-regression was performed to explore the sources of heterogeneity across the studies. conducted to assess the influence of each study. A P < 0.05 was considered statistically significant. Hardy-Weinberg equilibrium was checked in the control group for each included study using an online tool (https://ihg.gsf.de/cgi-bin/hw/hwa1.pl). All statistical analyses were performed using the "meta-package" in R (version 3.3.1). 23 3 | RESULTS
| Characteristics of the included studies
In this study, we analyzed the associations between three types of birth defects (NTDs, CHD, and DS) and four types of APOs (RPL, PE, PA, and IUGR) and the MTHFR C677T and A1298C polymorphisms.
Tables S1 to S11 present the characteristics of all included studies.
For the RPL C677T studies, there were 4338 cases and 4649 controls. 
| Overall meta-analysis
The dominant genetic model (CT+TT vs CC and AC+CC vs AA) was applied on the basis of the theory of Thakkinstian et al. 22 For RPL C677T studies, the pooled OR was 1.23, and the 95% CI was (1.05- C677T studies, the pooled OR was 1.65, and the 95% CI was (1.39-1.95). For DS A1298C studies, the pooled OR was 1.11, and the 95% CI was (0.93-1.33). In summary, only C677T was found to be significantly associated with RPL, NTDs, and DS with a moderate impact.
No significant association was found between A1298C and RPL, PE, NTDs, and DS. Forest plots for these 11 studies are presented in Fig- ures S1 to S11.
| Publication bias
There was no publication bias found for all 11 meta-analyses based on
Begg and Egger tests.
| Subgroup and sensitivity analyses
There was a large heterogeneity (I 2 > 50%) detected in the overall meta-analysis results of the RPL C677T and A1298C, IUGR C677T, and CHD C677T studies. Therefore, meta-regression analysis was required to explore the sources of heterogeneity. A series of univariate models were conducted by adding single covariate, including publication year, region, development level of the country, and genotyping methods.
For the RPL C677T meta-analysis, only the development level of the country had a notable impact (P < 0.05). Therefore, a subgroup analysis based upon the development level of the country was performed. After stratification by development level of the country, the I 2 was 22.6% for developed countries with an OR of 0.87 and 95% CI of 0.68-1.11, indicating C677T was not significantly related to RPL in developed countries. In developing countries, the I 2 still remained relatively high (56.2%). A further regression test was then performed to assess heterogeneity, and the regions were found to be significantly related (P = 0.0457). However, stratification by regions was not performed as the number in each subgroup was too small. Instead, a sensitivity analysis was performed for RPL C677T studies in the developing countries, and after omitting the study by Ozturk Ozdemir (2012) (Table S1), the I 2 was reduced to 42.9%, but the OR and 95% CI remained similar (1.38 with 1.17-1.63 vs 1.36 with 1.22-1.51 before and after study omission, respectively). Although the association between C677T and RPL in developing countries was significant, the effect was only moderate. As for the RPL A1298C metaanalysis, studies by Kamelia Farahmand (2015) and Yulei Cao (2014) (Table S2) had a large impact on the overall heterogeneity. After omitting these two studies, the heterogeneity was reduced from 92.7% to 39.7%, but the conclusion remained the same: No significant relationship was found as the CI crossed the null (OR, 1.04; 95% CI, 0.93-1.18).
For the IUGR C677T meta-analysis, the results of studies by Fatemeh Mirzaei (2013) and Vesna Livrinova (2012) (Table S6) For the CHD C677T meta-analysis, the study by Lina Wang (2017) ( Summary of the meta-analysis final results after stratification and/or sensitivity analyses is presented in Table 1 .
| DISCUSSION
Recent investigations on the pathophysiology of birth defects and
APOs have found elevated levels of Hcy in blood, which causes endothelial cell injury that can then lead to a wide range of diseases, may be a risk factor. 24 High levels of Hcy may be caused by dietary deficien- 
| Summary of main findings
In our meta-analysis, we collected studies for three types of birth defects, NTDs, CHD, and DS, and four types of APOs, RPL, PE, PA, and IUGR, for meta-analysis. The aim of this study was to comprehensively review the effect of maternal MTHFR C677T and A1298C on APOs or offspring with defects. From our results, there was no significant association found between these two polymorphisms and PE.
Only C677T was meta-analyzed for PA studies, and no significant relationship was found. For NTDs studies, only C677T, but not A1298C, was significantly associated with this type of birth defect; however, this effect was moderate (OR = 1.24). Similarly, in DS studies, only C677T was found to be significantly related (OR = 1.65).
Subgroup and sensitivity analyses were performed for the RPL, IUGR, and CHD studies, as these studies had large heterogeneity. It is very interesting to find that after stratification analysis based on country development level, C677T was determined to be significantly related to RPL in developing countries but not in developed countries. C677T in RPL, but subgroup analysis was not successful as no source of heterogeneity was identified among region, publication year, control source, and sample size. 26 Another meta-analysis regarding A1298C and RPL found no association. 27 A meta-analysis for PE published in 2015 found that C677T was a risk factor in Asian populations (OR = 1.47; 95% CI = 1.09-1.98), but not in Caucasian and Latino 
| Limitations
There are some limitations to our study. First, we only included published literature in the languages of English and Chinese and searched in only five databases. It is possible we missed some eligible studies.
Second, there was still moderate heterogeneity (I 2 ≈ 40%) in some of the meta-analysis after stratification, but the results were robust after subgroup and sensitivity analyses. The heterogeneity might be due to failure to sufficiently record ethnicity or race identification or lifestyle factors associated with folate use in the original studies.
| Conclusions
In conclusion, we found carriage of rare MTHFR mutants was associated with an approximately 1.2-to 1.6-fold increased risk of having a child with RPL, NTD, or DS. However, this effect was modest and might vary between regions or populations. The possible reason for no significant association being observed between RPL in developed countries might be the diet structure, the folic acid fortification program, or simply a better living environment.
To date, efforts have been made to assess red blood cell folate concentrations and Hcy blood levels in pregnant women. However, no guidelines have been established for predicting the risk of having APOs or birth defects in pregnant women. Therefore, this area may be of interest for further studies.
